Stay updated on PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Sign up to get notified when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.

Latest updates to the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page
- Check5 days agoChange DetectedThe page's revision label was updated from v3.5.4 to v3.5.5, representing a small maintenance update without visible content changes.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA new revision label v3.5.4 was added, replacing the previous v3.5.3 to denote a minor build/version update for the page. This reflects maintenance or a status update rather than changes to study information or outcomes.SummaryDifference0.1%

- Check40 days agoChange DetectedRevision label updated from v3.5.2 to v3.5.3, signaling an updated version of the page documentation. Aside from this metadata update, the page content and structure appear unchanged.SummaryDifference0.1%

- Check55 days agoChange DetectedFooter shows site revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check83 days agoChange DetectedAdministrative revision update: added v3.5.0 and removed v3.4.3.SummaryDifference0.1%

- Check90 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

Stay in the know with updates to PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.